Johnson & Johnson

03/17/2023 | Press release | Distributed by Public on 03/17/2023 06:56

TREMFYA® (guselkumab) Real-World Data Analyses Show Greater Treatment Persistence Than IL-17s in Both Bio-naïve and Bio-experienced Patients Living With Moderate to Severe[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.